nach oben

Pathology & Oncology Research

Erschienen in:

09.07.2019 | Original Article

Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma

verfasst von: Chao Liu, Dingwei Xu, Bai Xue, Bolin Liu, Jing Li, Jie Huang

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and occurs in people with chronic liver diseases. Current treatment methods include surgery, transplant, and chemotherapy. Our study demonstrates runt-related transcription factor 1 (RUNX1) as a novel molecule in the initiation and development of HCC, and the role of its interaction with vascular endothelial growth factor A (VEGFA) in HCC. We showed the suppressive role of RUNX1 in the proliferation and migration of hepatocytes. In addition, the repressor RUNX1 functioned as a transcription factor on the promoter of VEGFA to inhibit the expression of VEGFA. Study in the HCC cells demonstrated that the suppression of HCC proliferation and migration was masked in the presence of overexpressed VEGFA. Introduction of RUNX1 into HCC mice model significantly limited the tumor growth. In summary, our study demonstrated that RUNX1 functions as a repressor in the HCC and this suppressive function was dependent on its effect on VEGFA.

Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM (2017) Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev 18(4):863–872. https://doi.org/10.22034/APJCP.2017.18.4.863 CrossRefPubMedPubMedCentral

Gomes MA, Priolli DG, Tralhão JG, Botelho MF (2013) Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras 59(5):514–524. https://doi.org/10.1016/j.ramb.2013.03.005 CrossRefPubMed

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255. https://doi.org/10.1016/S0140-6736(11)61347-0 CrossRefPubMed

Forner A, Gilabert M, Bruix J, Raoul JL (2014) Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11(9):525–535. https://doi.org/10.1038/nrclinonc.2014.122 CrossRefPubMed

Sood R, Kamikubo Y, Liu P (2017) Role of RUNX1 in hematological malignancies. Blood 129(15):2070–2082. https://doi.org/10.1182/blood-2016-10-687830 CrossRefPubMedPubMedCentral

Ito Y, Bae SC, Chuang LS (2015) The RUNX family: developmental regulators in cancer. Nat Rev Cancer 15(2):81–95. https://doi.org/10.1038/nrc3877 CrossRefPubMed

Wu J, Huang G, Ratner N (2015) Runx1: a new driver in neurofibromagenesis. Oncoscience 2(11):904–905. https://doi.org/10.18632/oncoscience.266 CrossRefPubMedPubMedCentral

Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F (2015) Proteomics. Tissue-based map of the human proteome. Science 347(6220):1260419. https://doi.org/10.1126/science.1260419 CrossRefPubMed

Goyama S, Huang G, Kurokawa M, Mulloy JC (2015) Posttranslational modifications of RUNX1 as potential anticancer targets. Oncogene 34(27):3483–3492. https://doi.org/10.1038/onc.2014.305 CrossRefPubMed

10.

Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4–10. https://doi.org/10.1159/000088478 CrossRefPubMed

11.

Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, Kliche S, Albert J, Sparwasser T, Sakaguchi S, Westendorf AM, Schadendorf D, Buer J, Helfrich I (2012) Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 209(11):2001–2016. https://doi.org/10.1084/jem.20111497 CrossRefPubMedPubMedCentral

12.

Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13(12):871–882. https://doi.org/10.1038/nrc3627 CrossRefPubMedPubMedCentral

13.

Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437(7058):497–504. https://doi.org/10.1038/nature03987 CrossRefPubMed

14.

Shibuya M (2013) Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153(1):13–19. https://doi.org/10.1093/jb/mvs136 CrossRefPubMed

15.

Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 212(2):139–148. https://doi.org/10.1084/jem.20140559 CrossRefPubMedPubMedCentral

16.

Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, Schweitzer N, Tornillo L, Kanarek N, Quagliata L, Zreik F, Porat RM, Finkelstein R, Reuter H, Koschny R, Ganten T, Mogler C, Shibolet O, Hess J, Breuhahn K, Grunewald M, Schirmacher P, Vogel A, Terracciano L, Angel P, Ben-Neriah Y, Pikarsky E (2014) Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 4(6):730–743. https://doi.org/10.1158/2159-8290.CD-13-0782 CrossRefPubMed

17.

Gascon E, Gaillard S, Malapert P, Liu Y, Rodat-Despoix L, Samokhvalov IM, Delmas P, Helmbacher F, Maina F, Moqrich A (2010) Hepatocyte growth factor-Met signaling is required for Runx1 extinction and peptidergic differentiation in primary nociceptive neurons. J Neurosci 30(37):12414–12423. https://doi.org/10.1523/JNEUROSCI.3135-10.2010 CrossRefPubMedPubMedCentral

18.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES (2011) Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res 71(7):2761–2771. https://doi.org/10.1158/0008-5472.CAN-10-0402 CrossRefPubMed

19.

Bowers SR, Calero-Nieto FJ, Valeaux S, Fernandez-Fuentes N, Cockerill PN (2010) Runx1 binds as a dimeric complex to overlapping Runx1 sites within a palindromic element in the human GM-CSF enhancer. Nucleic Acids Res 38(18):6124–6134. https://doi.org/10.1093/nar/gkq356 CrossRefPubMedPubMedCentral

20.

Klaunig JE, Pereira MA, Ruch RJ, Weghorst CM (1988) Dose-response relationship of diethylnitrosamine-initiated tumors in neonatal balb/c mice: effect of phenobarbital promotion. Toxicol Pathol 16(3):381–385. https://doi.org/10.1177/019262338801600310 CrossRefPubMed

21.

Wang L, Brugge JS, Janes KA (2011) Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci U S A 108(40):E803–E812. https://doi.org/10.1073/pnas.1103423108 CrossRefPubMedPubMedCentral

22.

Mercado-Matos J, Matthew-Onabanjo AN, Shaw LM (2017) RUNX1 and breast cancer. Oncotarget 8(23):36934–36935. https://doi.org/10.18632/oncotarget.17249 CrossRefPubMedPubMedCentral

23.

Barnum KJ, O'Connell MJ (2014) Cell cycle regulation by checkpoints. Methods Mol Biol 1170:29–40. https://doi.org/10.1007/978-1-4939-0888-2_2 CrossRefPubMedPubMedCentral

24.

Cai D, Chen SC, Prasad M, He L, Wang X, Choesmel-Cadamuro V, Sawyer JK, Danuser G, Montell DJ (2014) Mechanical feedback through E-cadherin promotes direction sensing during collective cell migration. Cell 157(5):1146–1159. https://doi.org/10.1016/j.cell.2014.03.045 CrossRefPubMedPubMedCentral

25.

Battaglia RA, Delic S, Herrmann H, Snider NT (2018) Vimentin on the move: new developments in cell migration. F1000Res 7. https://doi.org/10.12688/f1000research.15967.1 CrossRef

26.

Kidd ME, Shumaker DK, Ridge KM (2014) The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 50(1):1–6. https://doi.org/10.1165/rcmb.2013-0314TR CrossRefPubMedPubMedCentral

27.

Xu X, Wang Y, Chen Z, Sternlicht MD, Hidalgo M, Steffensen B (2005) Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res 65(1):130–136PubMed

28.

Srivastava VK, Gara RK, Rastogi N, Mishra DP, Ahmed MK, Gupta S, Goel MM, Bhatt ML (2014) Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev 15(7):3261–3265CrossRefPubMed

Titel: Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma
verfasst von: Chao Liu
Dingwei Xu
Bai Xue
Bolin Liu
Jing Li
Jie Huang
Publikationsdatum: 09.07.2019
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 2/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00694-1

Springer Medizin

Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

High Expression of Angiopoietin-like Protein 4 in Advanced Colorectal Cancer and its Association with Regulatory T Cells and M2 Macrophages

Statin Therapy and Survival among Women with Ovarian Cancer: how much of it Is True?

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma

Syndecan-1 in Liver Diseases

Solid-pseudopapillary Neoplasms of the Pancreas is still an Enigma: a Clinicopathological Review

Irinotecan-Induced Mucositis Is Associated with Goblet Cell Dysregulation and Neural Cell Damage in a Tumour Bearing DA Rat Model

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie